CJ Corporation Q1 2026: Revenue Climbs 8% but Operating Profit Slides 13% as BIO Segment Stumbles
CJ Corporation (KRX: 001040), South Korea's diversified conglomerate spanning food, life sciences, logistics, and entertainment, reported first-quarter 2026 consolidated revenue of KRW 11.45 trillion (approximately USD 8.3 billion), up 8.0% year-on-year. However, operating profit fell 13.2% to KRW 460.7 billion, with the company's life sciences unit taking the heaviest blow — posting a 62.3% collapse in operating profit that weighed on group-level margins.
Segment Breakdown: BIO Pressure Offsets Broad Revenue Growth
Four segments comprising food & food services, life sciences (BIO), logistics & new retail, and entertainment & media all reported revenue gains, yet profitability diverged sharply.
Life Sciences (BIO) — which covers CJ CheilJedang's amino acid businesses including animal-nutrition feed additives — saw net revenue slip 5.4% to KRW 1.35 trillion while operating profit cratered to KRW 52.5 billion from KRW 139.1 billion in Q1 2025, a 62.3% year-on-year decline. The unit's operating margin compressed to below 4%, down from roughly 10% in the comparable period, as global amino acid prices remained under pressure amid persistent oversupply in key markets. At the subsidiary level, CJ CheilJedang's standalone BIO operating profit reached KRW 5.5 billion in the quarter — a fraction of the KRW 202.1 billion recorded for the full year 2025.
Food & Food Services held up comparatively well: net revenue rose 5.7% to KRW 3.87 trillion and operating profit grew 7.0% to KRW 155.2 billion. The food segment benefited from continued strength in K-Food exports — including bibimbap, dumplings (mandu), and processed chicken — as well as premium pricing in domestic staples. Sugar holds a 77% domestic market share and commercial canned ham a 67% share. CJ FreshWay, the B2B food distribution arm, posted Q1 2026 revenue of KRW 631.5 billion (+3.8% YoY) with operating profit of KRW 8.1 billion.
Logistics & New Retail posted the strongest absolute operating profit at KRW 279.0 billion (-0.7% YoY) on revenue of KRW 4.86 trillion (+11.5%), underpinned by CJ Logistics' domestic parcel and cross-border freight volumes, alongside growth in CJ Olive Young's health and beauty retail network.
Entertainment & Media narrowed its operating loss from KRW 29.6 billion in Q1 2025 to KRW 23.9 billion this quarter, driven by CJ ENM and CJ CGV. CJ ENM's total Q1 2026 revenue reached KRW 1.33 trillion, with the film & drama division surging 44.8% year-on-year to KRW 457.3 billion — reflecting strong international demand for Korean dramas and content licensing. The media platform unit (Tving/tvN) added 11.6% to KRW 326.8 billion. CJ CGV's global theater network drew 33.19 million admissions in Q1 2026, up 8% year-on-year, aided by the domestic hit film The Man Living with a King and recovering cinema attendance in Vietnam, Indonesia, and Turkey.
Consolidated Bottom Line
Group-level net income came in at KRW 174.3 billion, up 22.2% from KRW 142.6 billion in Q1 2025, helped by improved non-operating items. However, net income attributable to the parent company dropped 47.2% to KRW 75.7 billion from KRW 143.3 billion, as a larger share of earnings was absorbed by non-controlling interests in listed subsidiaries including CJ CheilJedang (097950), CJ ENM (035760), Studio Dragon (253450), and CJ CGV (079160). Earnings per share fell to KRW 2,256 from KRW 4,271 a year earlier.
Pre-tax income rose 6.3% to KRW 282.2 billion, reflecting lower financial charges compared to the prior period.
Balance Sheet
As of March 31, 2026, CJ Corporation held consolidated total assets of KRW 48.39 trillion, up from KRW 46.97 trillion at year-end 2025. Total liabilities increased to KRW 31.22 trillion from KRW 29.95 trillion, while total equity edged up to KRW 17.17 trillion. Cash and equivalents stood at KRW 2.57 trillion. The conglomerate comprises 470 consolidated entities — 76 domestic and 394 overseas.
Outlook
CJ Corporation has flagged global amino acid price recovery as a key near-term variable. The BIO segment's pronounced weakness in Q1 2026 continues a trend seen through 2025, as lysine and other feed-additive prices remain depressed. Management is pursuing cost-efficiency measures and capacity optimisation across overseas BIO plants in Indonesia, China, Brazil, the United States, and Malaysia.
On the growth side, management is accelerating CJ ENM's content pipeline for the remainder of 2026, with Studio Dragon expanding drama licensing into North America and Europe. CJ Logistics is also targeting cross-border e-commerce fulfilment expansion in Southeast Asia to sustain logistics revenue momentum.
Sources: CJ Corporation Q1 2026 Quarterly Report (DART, filed 15 May 2026), DART rcept_no 20260515002418
